A PYMNTS Company

Hoping for EU approval of Synthes acquisition, J&J will sell trauma unit to Biomet

 |  April 4, 2012

Johnson & Johnson announced on Tuesday that it will divest the trauma segment of DePuy Orthopaedics (its medical device division) in hopes of winning EU approval for its acquisition of Synthes. The asset will be sold to Biomet for $280 million.

Full content: Philadelphia Inquirer


Related contentAnalyzing Medical Device Mergers